Baseline Laboratory Testing for a 19-Year-Old with BMI 42 kg/m²
This patient requires screening for type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease (NAFLD) with hemoglobin A1C, fasting lipid panel, and liver function tests (ALT/AST).
Primary Screening Tests
Given this patient's severe obesity (BMI 42 kg/m² = Class III obesity) and young age, the following laboratory tests should be ordered based on current diabetes and obesity guidelines:
Essential Tests
Hemoglobin A1C - Primary screening test for diabetes/prediabetes 1, 2
- Alternative: Fasting plasma glucose (FPG) or 2-hour 75-g oral glucose tolerance test
- All three tests are equally appropriate, but A1C is most practical 1
Fasting lipid panel - Screen for dyslipidemia 1, 3
- Includes total cholesterol, HDL, LDL, and triglycerides
- HDL <35 mg/dL and/or triglycerides >250 mg/dL are additional diabetes risk factors
Liver function tests (ALT and AST) - Screen for NAFLD 4, 5
- ALT is the preferred screening test for NAFLD in young adults with obesity
- Consider abdominal ultrasound if ALT elevated (>26 IU/L in males, >22 IU/L in females)
Additional Recommended Tests
Basic metabolic panel (BMP) or comprehensive metabolic panel (CMP) 6
- Includes electrolytes, creatinine, and estimated glomerular filtration rate (eGFR)
- Screens for kidney dysfunction associated with obesity and potential diabetes
Thyroid-stimulating hormone (TSH) 6
- Excludes hypothyroidism as a secondary cause of obesity
- Though routine screening for hypothyroidism is not universally recommended in obesity 7, it remains commonly ordered and clinically useful
Clinical Reasoning
This patient meets multiple high-risk criteria for type 2 diabetes screening 1:
- BMI ≥25 kg/m² (significantly exceeded at 42 kg/m²)
- Age 19 years (guidelines recommend screening begin at age 35, but earlier with obesity and risk factors)
- Severe obesity itself is a major risk factor
The 2023 American Diabetes Association guidelines specifically state that testing should be considered in adults of any age with overweight or obesity (BMI ≥25 kg/m²) who have one or more additional risk factors 1. At BMI 42 kg/m², this patient has severe obesity, which constitutes both the primary criterion and an additional risk factor ("severe obesity" is explicitly listed as a condition associated with insulin resistance) 1, 3.
Evidence Quality and Strength
The recommendations are based on high-quality guideline evidence from the American Diabetes Association (2023) 1, which represents the most recent and authoritative guidance. These guidelines are consistently supported across multiple years 8, 3, 9, 2 with only minor updates, demonstrating stability of recommendations.
Research evidence confirms significant underscreening: A 2025 study found that among 333,110 youth with obesity, only 26% were screened for diabetes, dyslipidemia, or NAFLD, and when screened, 56% had abnormal lipids, 44% had elevated liver markers, and 14% had prediabetes or diabetes 5. This underscores the critical importance of systematic screening in this population.
Important Caveats
If initial tests are normal, repeat testing should occur at minimum 3-year intervals, with consideration for more frequent testing given the severity of obesity 1
If prediabetes is identified (A1C 5.7-6.4%, FPG 100-125 mg/dL, or 2-hour glucose 140-199 mg/dL), annual testing is required 1, 3
Screen for additional cardiovascular risk factors: hypertension, physical inactivity, family history of diabetes, and consider screening for polycystic ovary syndrome if female 1
Avoid unnecessary testing: Routine screening for hyperinsulinemia is not recommended and represents overuse of testing 7